Immunotherapy drug is well tolerated in lung cancer patients with limited physical function, study suggests

by

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

Leave A Comment

Your email address will not be published. Required fields are marked *